Adjuvant therapy in gastric cancer: What is the optimal approach?

Takashi Taketa, Kazuki Sudo, Roopma Wadhawa, Mariela M. Blum, Jaffer A. Ajani

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Gastric cancer confers a poor prognosis even when diagnosed as localized disease. Multimodality therapy improves the cure rate of patients with localized cancer. However, adjunctive therapeutic approaches differ in different regions of the world. This review focuses on the current standards and unresolved issues based on updated literature on therapy for localized gastric cancer. In the USA, the Intergroup 0116 trial established the use of postoperative chemoradiotherapy as a standard for patients who have surgery first for treatment of gastric cancer. In Europe, the MAGIC trial investigating perioperative chemotherapy demonstrated a survival benefit for gastric cancer patients. Finally, in Asia, the ACTS-GC and CLASSIC trials investigating postoperative chemotherapy established this as the standard of care after primary surgery that included D2 dissection. It is clear, however, that surgery alone is insufficient to achieve the highest possible cure rates.

Original languageEnglish (US)
Pages (from-to)146-151
Number of pages6
JournalCurrent oncology reports
Volume15
Issue number2
DOIs
StatePublished - Apr 2013

Keywords

  • Adjuvant therapy
  • Biomarker
  • Gastric cancer
  • Postoperative
  • Preoperative

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Adjuvant therapy in gastric cancer: What is the optimal approach?'. Together they form a unique fingerprint.

Cite this